Clinical and immunological effects of human recombinant interleukin-2 given by repetitive weekly infusion to normal dogs.
Four normal adult dogs received two consecutive weekly cycles of human recombinant interleukin-2 (IL-2) by continuous infusion for 4 days/week. The dose of IL-2 given to each dog was 3 x 10(6) units m-2 day-1. Toxicities consisted of mild vomiting, diarrhea, and lethargy to varying degrees in all the dogs. These side-effects were reversed when the treatment was discontinued. Fever, tachypnea, and weight gain were not seen. A marked lymphocytosis and eosinophilia developed in all dogs after completion of each course of IL-2 (resulting in a more than sevenfold increase in each cell type) and persisted for more than 1 month in some. Fresh peripheral blood lymphocytes (PBL) obtained during this lymphocytosis mediated enhanced in vitro lysis of a natural-killer-cell-sensitive canine tumor cell line (CTAC). The in vitro proliferative responses of these same PBL to IL-2 could be detected earlier, progressed faster, and involved more cells than PBL tested prior to IL-2 infusion. Thus, a relatively well-tolerated regime of IL-2 in dogs can induce dramatic increases in lymphocyte numbers and activation, which is associated with augmentation of their in vitro antitumor reactivity. The clinical effectiveness of this immunotherapeutic approach remains to be tested in tumor-bearing dogs where it could serve as a relevant large-animal model for immunotherapy of cancer with IL-2.
Helfand
S C
SC
Department of Medical Sciences, University of Wisconsin-Madison.
Soergel
S A
SA
MacWilliams
P S
PS
Hank
J A
JA
Sondel
P M
PM
D000230:Adenocarcinoma / Q000188:drug therapy; D000818:Animals; D003602:Cytotoxicity, Immunologic; D004195:Disease Models, Animal; D004285:Dogs; D004334:Drug Administration Schedule; D007167:Immunotherapy; D007262:Infusions, Intravenous; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000097:blood / Q000633:toxicity; D008213:Lymphocyte Activation / Q000187:drug effects*; D008214:Lymphocytes / Q000187:drug effects / Q000502:physiology; D010641:Phenotype; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000097:blood / Q000633:toxicity; D013964:Thyroid Neoplasms / Q000188:drug therapy; D014407:Tumor Cells, Cultured
D007376:Interleukin-2; D011994:Recombinant Proteins